JPH0475920B2 - - Google Patents
Info
- Publication number
- JPH0475920B2 JPH0475920B2 JP59260115A JP26011584A JPH0475920B2 JP H0475920 B2 JPH0475920 B2 JP H0475920B2 JP 59260115 A JP59260115 A JP 59260115A JP 26011584 A JP26011584 A JP 26011584A JP H0475920 B2 JPH0475920 B2 JP H0475920B2
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- cells
- nutrient medium
- chloride
- inducing factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000006992 Interferon-alpha Human genes 0.000 claims description 49
- 108010047761 Interferon-alpha Proteins 0.000 claims description 49
- 102000008070 Interferon-gamma Human genes 0.000 claims description 39
- 108010074328 Interferon-gamma Proteins 0.000 claims description 39
- 229940044627 gamma-interferon Drugs 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 31
- 210000000265 leukocyte Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 235000015097 nutrients Nutrition 0.000 claims description 23
- 102000014150 Interferons Human genes 0.000 claims description 22
- 108010050904 Interferons Proteins 0.000 claims description 22
- 229940079322 interferon Drugs 0.000 claims description 21
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 235000019270 ammonium chloride Nutrition 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 108010062580 Concanavalin A Proteins 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 102000003996 Interferon-beta Human genes 0.000 claims description 5
- 108090000467 Interferon-beta Proteins 0.000 claims description 5
- 241000711408 Murine respirovirus Species 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000003226 mitogen Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 206010018910 Haemolysis Diseases 0.000 claims description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 2
- 239000000147 enterotoxin Substances 0.000 claims description 2
- 231100000655 enterotoxin Toxicity 0.000 claims description 2
- 238000002523 gelfiltration Methods 0.000 claims description 2
- 230000008588 hemolysis Effects 0.000 claims description 2
- 230000001885 phytohemagglutinin Effects 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 101710146739 Enterotoxin Proteins 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ãããçœè¡çããã³ããã¬ã³ãã€ã³ã¿
ãŒããšãã³ã®é次çãªè£œé æ¹æ³ã«é¢ããã
ãŒããšãã³ã®é次çãªè£œé æ¹æ³ã«é¢ããã
æ¬çºæã«åŸããåäžã®çŽ°èéå£ããïŒå·¥çšã§Î±
âããã³Î³âã€ã³ã¿ãŒããšãã³ã補é ããæ¹æ³ã
æäŸãããåŸã€ãŠãæ¬çºæã¯ãã€ã³ã¿ãŒããšãã³
ç£çèœåããã€ãå ¥æã§ããéãéå®çã§ããã
ãçœè¡çã®æ倧éãã€æé©ã®å©çšãå¯èœãšããã
ã®ã§ããã
âããã³Î³âã€ã³ã¿ãŒããšãã³ã補é ããæ¹æ³ã
æäŸãããåŸã€ãŠãæ¬çºæã¯ãã€ã³ã¿ãŒããšãã³
ç£çèœåããã€ãå ¥æã§ããéãéå®çã§ããã
ãçœè¡çã®æ倧éãã€æé©ã®å©çšãå¯èœãšããã
ã®ã§ããã
ããçœè¡çããããŠã€ã«ã¹ãçšããŠÎ±âã€ã³ã¿
ãŒããšãã³ãç£çãåŸãããšããã³åè£ä¿é²å å
ã®å©ãã«ãã€ãŠÎ³âã€ã³ã¿ãŒããšãã³ãç£çãåŸ
ãããšãç¥ãããŠãããåèšïŒã€ã®åã®ã€ã³ã¿ãŒ
ããšãã³ã®ç£çã¯ãããçœè¡çãå ¥æã§ãããé
å®çã§ãããšããäºå®ã«ãã€ãŠéå®ãããŠããã
ããã«å¯Ÿããçæ³ã«ã¯ãïŒã€ã®åã®ã€ã³ã¿ãŒããš
ãã³ãå¿ èŠã§ããããã®çç±ã¯ãçžç°ãªãã€ã³ã¿
ãŒããšãã³ã®åãçžç°ãªã奜éœåãªæ§è³ªãæããŠ
ããïŒåŸã€ãŠãαâã€ã³ã¿ãŒããšãã³ã¯ããšãã
ãæãŠã€ã«ã¹æŽ»æ§ã瀺ããγâã€ã³ã¿ãŒããšãã³
ã¯æè «ç掻æ§ã瀺ãïŒããã€ãããã®ã€ã³ã¿ãŒã
ãšãã³ã®çµåãã®é©çšã¯ãçžç°ãªãã€ã³ã¿ãŒããš
ãã³ãäºãã«ä»ã®æŽ»æ§ïŒæãŠã€ã«ã¹äœçšãæè «ç
äœçšãå ç«èª¿ç¯äœçšïŒãå¢åŒ·ããå Žåã«æãŸã
ããïŒã€ã®åã®ã€ã³ã¿ãŒããšãã³ã¯ãéå®ããã
éã§ãããå ¥æå¯èœãªçœè¡çããç£çãããã®
ã§ãïŒã€ã®ã€ã³ã¿ãŒããšãã³ã®åã®ç£çã¯ä»ã®å
ã®ç£çãé€å€ããã
ãŒããšãã³ãç£çãåŸãããšããã³åè£ä¿é²å å
ã®å©ãã«ãã€ãŠÎ³âã€ã³ã¿ãŒããšãã³ãç£çãåŸ
ãããšãç¥ãããŠãããåèšïŒã€ã®åã®ã€ã³ã¿ãŒ
ããšãã³ã®ç£çã¯ãããçœè¡çãå ¥æã§ãããé
å®çã§ãããšããäºå®ã«ãã€ãŠéå®ãããŠããã
ããã«å¯Ÿããçæ³ã«ã¯ãïŒã€ã®åã®ã€ã³ã¿ãŒããš
ãã³ãå¿ èŠã§ããããã®çç±ã¯ãçžç°ãªãã€ã³ã¿
ãŒããšãã³ã®åãçžç°ãªã奜éœåãªæ§è³ªãæããŠ
ããïŒåŸã€ãŠãαâã€ã³ã¿ãŒããšãã³ã¯ããšãã
ãæãŠã€ã«ã¹æŽ»æ§ã瀺ããγâã€ã³ã¿ãŒããšãã³
ã¯æè «ç掻æ§ã瀺ãïŒããã€ãããã®ã€ã³ã¿ãŒã
ãšãã³ã®çµåãã®é©çšã¯ãçžç°ãªãã€ã³ã¿ãŒããš
ãã³ãäºãã«ä»ã®æŽ»æ§ïŒæãŠã€ã«ã¹äœçšãæè «ç
äœçšãå ç«èª¿ç¯äœçšïŒãå¢åŒ·ããå Žåã«æãŸã
ããïŒã€ã®åã®ã€ã³ã¿ãŒããšãã³ã¯ãéå®ããã
éã§ãããå ¥æå¯èœãªçœè¡çããç£çãããã®
ã§ãïŒã€ã®ã€ã³ã¿ãŒããšãã³ã®åã®ç£çã¯ä»ã®å
ã®ç£çãé€å€ããã
ïŒã€ã®ãã€åäžã®çœè¡çå¹é€ããαâããã³Î³
âã€ã³ã¿ãŒããšãã³ãé次çã«èª¿è£œããæ¹æ³ãç·Ž
ãããšãæ¬çºæã®ç®çã§ãããåäžã®çŽ°èéå£ã
ãæ°åã«ããã€ãŠÎ±âã€ã³ã¿ãŒããšãã³ãç£çã
ããå€ãã®è©Šã¿ããªããããããããªããããã
ãã®è©Šã¿ã¯æåããªãã€ãããã®çç±ã¯ã现èã«
ãã€ãŠç£çãããå€éã®Î±âã€ã³ã¿ãŒããšãã³ã
现èã«äœçšããŠã现èãåå¿æ§ã®äœãç¶æ ã«ãã
ãã®çµæã次ã®èªçºæ®µéã«ãããŠã现èã®Î±âã€
ã³ã¿ãŒããšãã³ç£çèœåã極端ã«æžå°ããããã§
ããã
âã€ã³ã¿ãŒããšãã³ãé次çã«èª¿è£œããæ¹æ³ãç·Ž
ãããšãæ¬çºæã®ç®çã§ãããåäžã®çŽ°èéå£ã
ãæ°åã«ããã€ãŠÎ±âã€ã³ã¿ãŒããšãã³ãç£çã
ããå€ãã®è©Šã¿ããªããããããããªããããã
ãã®è©Šã¿ã¯æåããªãã€ãããã®çç±ã¯ã现èã«
ãã€ãŠç£çãããå€éã®Î±âã€ã³ã¿ãŒããšãã³ã
现èã«äœçšããŠã现èãåå¿æ§ã®äœãç¶æ ã«ãã
ãã®çµæã次ã®èªçºæ®µéã«ãããŠã现èã®Î±âã€
ã³ã¿ãŒããšãã³ç£çèœåã極端ã«æžå°ããããã§
ããã
æ¬çºæã¯ãå€éã®Î±âã€ã³ã¿ãŒããšãã³ã§Î³â
ã€ã³ã¿ãŒããšãã³ç£çç³»ãåŠçããåŸã§ãããã
ã®ç³»ã¯äœåå¿ç¶æ ã«è³ãããäžæ¹ãã€ã³ã¿ãŒããš
ãã³ã¯æªåŠçè©Šæã®å Žåããå€éã«ç£çããããš
ããèªèã«åºã¥ããŠããããã®ããšã¯Î±âã€ã³ã¿
ãŒããšãã³ç£ç段éã®çµããã«ãèµ·ãããããã«
ãã€ãŠå€éã®Î±âã€ã³ã¿ãŒããšãã³ãåŸãããã
ããŠåæã«ãγâã€ã³ã¿ãŒããšãã³ç£ç现èã®ã€
ã³ã¿ãŒããšãã³ç£çèœåãç¶æãããããã«å¢å€§
ããã
ã€ã³ã¿ãŒããšãã³ç£çç³»ãåŠçããåŸã§ãããã
ã®ç³»ã¯äœåå¿ç¶æ ã«è³ãããäžæ¹ãã€ã³ã¿ãŒããš
ãã³ã¯æªåŠçè©Šæã®å Žåããå€éã«ç£çããããš
ããèªèã«åºã¥ããŠããããã®ããšã¯Î±âã€ã³ã¿
ãŒããšãã³ç£ç段éã®çµããã«ãèµ·ãããããã«
ãã€ãŠå€éã®Î±âã€ã³ã¿ãŒããšãã³ãåŸãããã
ããŠåæã«ãγâã€ã³ã¿ãŒããšãã³ç£ç现èã®ã€
ã³ã¿ãŒããšãã³ç£çèœåãç¶æãããããã«å¢å€§
ããã
æ¬çºæã«åŸã€ãŠãè¡æ¶²ã®æ·¡é»èç»åãåé¢ãã
èµ€è¡çãé€å»ããé©åœãªæ é€å¹å°äžã«çœè¡çãæž
æ¿ãããããŠÎ±âã€ã³ã¿ãŒããšãã³èªçºå åãçš
ãããã³Î³âã€ã³ã¿ãŒããšãã³èªçºå åãçšããŠ
åŠçããããšã«ãã€ãŠÎ±âããã³Î³âã€ã³ã¿ãŒã
ãšãã³ã調補ããæ¹æ³ãæäŸããããã®æ¹æ³ã¯ã
è¡æ¶²ã®çœè¡çïŒæ·¡é»èïŒç»åãåé¢ããèµ€è¡çã
é€å»ãé©åœãªæ é€å¹å°äžã«ãã®çœè¡çãæžæ¿ãã
åŸã«åŸãããæžæ¿æ¶²ãαâãŸãã¯Î²âã€ã³ã¿ãŒã
ãšãã³ã§äºååŠçããããšãαâã€ã³ã¿ãŒããšã
ã³èªçºå åãšæ¥è§Šãããããšãαâã€ã³ã¿ãŒããš
ãã³ãå«æãã液äœã现èããåé¢ããææãªã
ã°Î±âã€ã³ã¿ãŒããšãã³ãååããããšãé©åœãª
æ é€å¹å°äžã§çŽ°èãæŽæµãæžæ¿ãããããšãåè£
ä¿é²å åã§åŠçããããšãγâã€ã³ã¿ãŒããšãã³
ãå«æãã液äœã现èããåé¢ããææãªãã°Î³
âã€ã³ã¿ãŒããšãã³ãååãããããŠææãªãã°
γâã€ã³ã¿ãŒããšãã³ããαâã€ã³ã¿ãŒããšãã³
ãé€å»ããããšãã«ãã€ãŠåäžã®çœè¡çå¹é€äžã§
é 次αâã€ã³ã¿ãŒããšãã³ããã³Î³âã€ã³ã¿ãŒã
ãšãã³ã調補ããããšãå«ãã§ããã
èµ€è¡çãé€å»ããé©åœãªæ é€å¹å°äžã«çœè¡çãæž
æ¿ãããããŠÎ±âã€ã³ã¿ãŒããšãã³èªçºå åãçš
ãããã³Î³âã€ã³ã¿ãŒããšãã³èªçºå åãçšããŠ
åŠçããããšã«ãã€ãŠÎ±âããã³Î³âã€ã³ã¿ãŒã
ãšãã³ã調補ããæ¹æ³ãæäŸããããã®æ¹æ³ã¯ã
è¡æ¶²ã®çœè¡çïŒæ·¡é»èïŒç»åãåé¢ããèµ€è¡çã
é€å»ãé©åœãªæ é€å¹å°äžã«ãã®çœè¡çãæžæ¿ãã
åŸã«åŸãããæžæ¿æ¶²ãαâãŸãã¯Î²âã€ã³ã¿ãŒã
ãšãã³ã§äºååŠçããããšãαâã€ã³ã¿ãŒããšã
ã³èªçºå åãšæ¥è§Šãããããšãαâã€ã³ã¿ãŒããš
ãã³ãå«æãã液äœã现èããåé¢ããææãªã
ã°Î±âã€ã³ã¿ãŒããšãã³ãååããããšãé©åœãª
æ é€å¹å°äžã§çŽ°èãæŽæµãæžæ¿ãããããšãåè£
ä¿é²å åã§åŠçããããšãγâã€ã³ã¿ãŒããšãã³
ãå«æãã液äœã现èããåé¢ããææãªãã°Î³
âã€ã³ã¿ãŒããšãã³ãååãããããŠææãªãã°
γâã€ã³ã¿ãŒããšãã³ããαâã€ã³ã¿ãŒããšãã³
ãé€å»ããããšãã«ãã€ãŠåäžã®çœè¡çå¹é€äžã§
é 次αâã€ã³ã¿ãŒããšãã³ããã³Î³âã€ã³ã¿ãŒã
ãšãã³ã調補ããããšãå«ãã§ããã
æ¬çºæã®æ¹æ³ã«åŸããåºçºç©è³ªãšããŠãïŒãïŒ
âã§48æé以äžè²¯èµããæåè¡åŠçã®ããè¡æ¶²ã®
æ·¡é»èç»åïŒçœè¡çïŒãçšããã
âã§48æé以äžè²¯èµããæåè¡åŠçã®ããè¡æ¶²ã®
æ·¡é»èç»åïŒçœè¡çïŒãçšããã
æåè¡ç©è³ªãšããŠãACD溶液ïŒã¯ãšã³é
žãã
ã³ã°ã«ã³ãŒã¹ãå«æãã溶液ïŒãŸãã¯çš®ã ã®å¡©åº
ïŒäŸãã°ãã¢ããã³ãŸãã¯ã°ã¢ãã³ïŒãè£å ãã
ACD溶液ãçšããããšãã§ãããéããçœè¡ç
ãæ¿åºŠåŸé é å¿åé¢ïŒäŸãã°ããã€ã³ãŒã«
ïŒFicollïŒãŸãã¯ãã«ã³ãŒã«ïŒPercollïŒïŒã«ãã€
ãŠããŸãã¯å¥œãŸããã¯å¡©åã¢ã³ã¢ããŠã ãçšããŠ
å®æœãã溶è¡ã«ãã€ãŠåãåºãããšãã§ããã
ã³ã°ã«ã³ãŒã¹ãå«æãã溶液ïŒãŸãã¯çš®ã ã®å¡©åº
ïŒäŸãã°ãã¢ããã³ãŸãã¯ã°ã¢ãã³ïŒãè£å ãã
ACD溶液ãçšããããšãã§ãããéããçœè¡ç
ãæ¿åºŠåŸé é å¿åé¢ïŒäŸãã°ããã€ã³ãŒã«
ïŒFicollïŒãŸãã¯ãã«ã³ãŒã«ïŒPercollïŒïŒã«ãã€
ãŠããŸãã¯å¥œãŸããã¯å¡©åã¢ã³ã¢ããŠã ãçšããŠ
å®æœãã溶è¡ã«ãã€ãŠåãåºãããšãã§ããã
奜ãŸããã¯ãæ¿çž®ããçœè¡çæžæ¿æ¶²ããïŒã10
âã®æž©åºŠãæãã0.5ã1.0ïŒ ã奜ãŸããã¯0.83ïŒ
ã®å¡©åã¢ã³ã¢ããŠã 溶液ãšãäœç©æ¯ïŒïŒïŒã20
ã§ã奜ãŸããã¯ïŒïŒïŒã§æ··åããããšã«ãã€ãŠå®
æœããããšãã§ããããã®æžæ¿æ¶²ããæ¹æããªã
ããŸãã¯æ¹æããªãã§ãïŒãïŒâã§ãïŒã20å
éã奜ãŸããã¯10åéã€ã³ããŠããŒãããã厩å£
ããèµ€è¡çããïŒäŸãã°ãé å¿åé¢ã«ãã€ãŠïŒçœ
è¡çãåé¢ããã奜ãŸããã¯ãïŒå®¹ééšã®çŽ°èæž
æ¿æ¶²ã«å¯ŸããŠ10éééšã®å¡©åã¢ã³ã¢ããŠã 溶液ã
çšããããšã«ããå¡©åã¢ã³ã¢ããŠã åŠçãç¹°ãè¿
ãããšã«ãã€ãŠå®æœããããšãã§ããã
âã®æž©åºŠãæãã0.5ã1.0ïŒ ã奜ãŸããã¯0.83ïŒ
ã®å¡©åã¢ã³ã¢ããŠã 溶液ãšãäœç©æ¯ïŒïŒïŒã20
ã§ã奜ãŸããã¯ïŒïŒïŒã§æ··åããããšã«ãã€ãŠå®
æœããããšãã§ããããã®æžæ¿æ¶²ããæ¹æããªã
ããŸãã¯æ¹æããªãã§ãïŒãïŒâã§ãïŒã20å
éã奜ãŸããã¯10åéã€ã³ããŠããŒãããã厩å£
ããèµ€è¡çããïŒäŸãã°ãé å¿åé¢ã«ãã€ãŠïŒçœ
è¡çãåé¢ããã奜ãŸããã¯ãïŒå®¹ééšã®çŽ°èæž
æ¿æ¶²ã«å¯ŸããŠ10éééšã®å¡©åã¢ã³ã¢ããŠã 溶液ã
çšããããšã«ããå¡©åã¢ã³ã¢ããŠã åŠçãç¹°ãè¿
ãããšã«ãã€ãŠå®æœããããšãã§ããã
粟補ããçœè¡çããã¢ããé
žããã³ãã¿ãã³ã
å«æãã现èå¹é€ã®æ é€æº¶æ¶²ïŒäŸãã°ãã€ãŒã°ã«
æ é€å¹å°ãPRMI 1640ããã«ããã¯
ïŒDulbecceïŒå€åœ¢MEMãã°ã©ã¹ãŽãŒïŒGlasgowïŒ
å€åœ¢MEMçïŒäžã§ã€ã³ããŠããŒãããããªãŒã
ã¯ã¬ãŒãåŠçãããŠããŠããããäžèšã®çµæã®å®
䟡ãªæ é€å¹å°ãçšããããšã奜ãŸããã
å«æãã现èå¹é€ã®æ é€æº¶æ¶²ïŒäŸãã°ãã€ãŒã°ã«
æ é€å¹å°ãPRMI 1640ããã«ããã¯
ïŒDulbecceïŒå€åœ¢MEMãã°ã©ã¹ãŽãŒïŒGlasgowïŒ
å€åœ¢MEMçïŒäžã§ã€ã³ããŠããŒãããããªãŒã
ã¯ã¬ãŒãåŠçãããŠããŠããããäžèšã®çµæã®å®
䟡ãªæ é€å¹å°ãçšããããšã奜ãŸããã
æ å émgïŒ
å¡©åã«ã«ã·ãŠã 175ã350
å¡©åã«ãªãŠã 300ã500
ç¡«é
žãã°ãã·ãŠã
ãŸãã¯å¡©åãã°ãã·ãŠã 175ã500
å¡©åãããªãŠã 5000ã7000
çé
žæ°ŽçŽ ãããªãŠã 200ã3500
çé
žäºæ°ŽçŽ ãããªãŠã 30ã150
ã°ã«ã³ãŒã¹ 500ã5500
ç¡é
žç¬¬äºé ïŒã0.2
现èæ°ã106ã108ã奜ãŸããã¯107现èïŒmlã«
調補ããã
調補ããã
çšããæ é€å¹å°ã«ãåç©ãŸãã¯ããã®è¡æž
ãŸã
ã¯ã¬ã³ãã°ãããªã³äžå«è¡æž ãè£å ããïŒ0.5ã
10ïŒ ïŒãæ é€å¹å°ã«ãæçç©è³ªïŒäŸãã°ãããªã
ã€ã·ã³ãŸãã¯ã²ã³ã¿ãã€ã·ã³ïŒãå ããããšã奜
ãŸããã
ã¯ã¬ã³ãã°ãããªã³äžå«è¡æž ãè£å ããïŒ0.5ã
10ïŒ ïŒãæ é€å¹å°ã«ãæçç©è³ªïŒäŸãã°ãããªã
ã€ã·ã³ãŸãã¯ã²ã³ã¿ãã€ã·ã³ïŒãå ããããšã奜
ãŸããã
次ãã§ã现èããαâãŸãã¯Î²âã€ã³ã¿ãŒããš
ãã³ã§åŠçããããã®ç®çã®ããã«ãèªçºå åäž
å«ã®ç²è£œãŸãã¯ç²Ÿè£œã®ã€ã³ã¿ãŒããšãã³ãã10ã
500IUïŒmlã奜ãŸããã¯200ã300IUïŒmlã®éã§çš
ããããšãã§ããããã®äºåçåŠçãã35ã39
âã奜ãŸããã¯37âã§ãïŒãïŒæéã奜ãŸããã¯
ïŒæéå®æœããã
ãã³ã§åŠçããããã®ç®çã®ããã«ãèªçºå åäž
å«ã®ç²è£œãŸãã¯ç²Ÿè£œã®ã€ã³ã¿ãŒããšãã³ãã10ã
500IUïŒmlã奜ãŸããã¯200ã300IUïŒmlã®éã§çš
ããããšãã§ããããã®äºåçåŠçãã35ã39
âã奜ãŸããã¯37âã§ãïŒãïŒæéã奜ãŸããã¯
ïŒæéå®æœããã
次ãã§ã现èããαâã€ã³ã¿ãŒããšãã³èªçºå
åã奜ãŸããã¯ã100ã800ã奜ãŸããã¯400èµ€è¡
çåéåäœïŒmlã®æ¿åºŠã§å¥œéœåã«é©çšããç²è£œãŸ
ãã¯ç²Ÿè£œã®ã»ã³ãã€ãŠã€ã«ã¹ãšæ¥è§Šãããã
åã奜ãŸããã¯ã100ã800ã奜ãŸããã¯400èµ€è¡
çåéåäœïŒmlã®æ¿åºŠã§å¥œéœåã«é©çšããç²è£œãŸ
ãã¯ç²Ÿè£œã®ã»ã³ãã€ãŠã€ã«ã¹ãšæ¥è§Šãããã
35ã39âã奜ãŸããã¯37âã®æž©åºŠã§ãïŒã48æ
éã奜ãŸããã¯15ã20æéãã€ã³ããŠããŒãã
ãããã®åŸã现èãæ°Žæ§çžããåé¢ããããã®äž
æž ã¯ãâ20âãïŒïŒâã®éã®æž©åºŠã§è²¯èµããããš
ãã§ãããããŸãã¯å ¬ç¥ã®æ¹æ³ã§ç²Ÿè£œããããšã
ã§ãããç²è£œã®Î±âã€ã³ã¿ãŒããšãã³ãå«æããŠ
ããã
éã奜ãŸããã¯15ã20æéãã€ã³ããŠããŒãã
ãããã®åŸã现èãæ°Žæ§çžããåé¢ããããã®äž
æž ã¯ãâ20âãïŒïŒâã®éã®æž©åºŠã§è²¯èµããããš
ãã§ãããããŸãã¯å ¬ç¥ã®æ¹æ³ã§ç²Ÿè£œããããšã
ã§ãããç²è£œã®Î±âã€ã³ã¿ãŒããšãã³ãå«æããŠ
ããã
次ãã§ã奜ãŸããã¯çççé£å¡©æ°ŽãçšããŠããš
ãããåèšçµæãæããæ é€å¹å°ãçšããŠïŒåã
现èãæŽæµããã现èãæŽæµããåŸãæ¿åºŠããæ
é€å¹å°äžã奜ãŸããã¯åèšé瀺ã®çµæãæããæ
é€å¹å°äžãïŒÃ106ã108ã®å€ã奜ãŸããã¯2.5Ã
107ã®å€ã«èª¿æŽãããåèšæ é€å¹å°ã¯ããããŸã
ã¯åç©ã®è¡æž ãŸãã¯ã°ãããªã³äžå«è¡æž ãã奜ãŸ
ããã¯ããã®ã°ãããªã³äžå«è¡æž ãã0.5ãïŒ
mgïŒmlã奜ãŸããã¯ïŒãïŒmgïŒmlã®æ¿åºŠïŒïŒãïŒ
ïŒ ïŒã§å«ãã§ããã
ãããåèšçµæãæããæ é€å¹å°ãçšããŠïŒåã
现èãæŽæµããã现èãæŽæµããåŸãæ¿åºŠããæ
é€å¹å°äžã奜ãŸããã¯åèšé瀺ã®çµæãæããæ
é€å¹å°äžãïŒÃ106ã108ã®å€ã奜ãŸããã¯2.5Ã
107ã®å€ã«èª¿æŽãããåèšæ é€å¹å°ã¯ããããŸã
ã¯åç©ã®è¡æž ãŸãã¯ã°ãããªã³äžå«è¡æž ãã奜ãŸ
ããã¯ããã®ã°ãããªã³äžå«è¡æž ãã0.5ãïŒ
mgïŒmlã奜ãŸããã¯ïŒãïŒmgïŒmlã®æ¿åºŠïŒïŒãïŒ
ïŒ ïŒã§å«ãã§ããã
次ãã§ãåŸ
æãγâã€ã³ã¿ãŒããšãã³èªçºå å
ãšæ¥è§Šãããããã®ç®çã®ããã奜ãŸããã¯ã³ã³
ã«ãããªã³ïŒ¡ããã€ããã ã¢ã°ã«ããã³ãŸãã¯ã¹
ã¿ãã€ãã³ã³ã«ã¹ã®ãšã³ããããã·ã³ãçšããã
ãšãã§ãããèªçºå åãšããŠãã³ã³ã«ãããªã³ïŒ¡
ãã奜éœåã«ã¯2.5ã30ugïŒmlããšããã15ugïŒ
mlã®æ¿åºŠã§çšããããšã奜ãŸããã
ãšæ¥è§Šãããããã®ç®çã®ããã奜ãŸããã¯ã³ã³
ã«ãããªã³ïŒ¡ããã€ããã ã¢ã°ã«ããã³ãŸãã¯ã¹
ã¿ãã€ãã³ã³ã«ã¹ã®ãšã³ããããã·ã³ãçšããã
ãšãã§ãããèªçºå åãšããŠãã³ã³ã«ãããªã³ïŒ¡
ãã奜éœåã«ã¯2.5ã30ugïŒmlããšããã15ugïŒ
mlã®æ¿åºŠã§çšããããšã奜ãŸããã
èªçºã¯ãéåžžã35ã39âã奜ãŸããã¯37âã®æž©
床ã§ãïŒã48æéã奜ãŸããã¯12ã16æéå®æœã
ãããã®èªçºå åã¯ãææãªãã°æå®ã®æéïŒäŸ
ãã°ãïŒæéïŒã®åŸã«æŽæµã«ãã€ãŠé€å»ããŠãã
ããããã®å·¥çšã¯çç¥ããŠãããããã®çç±ã¯ã
èªçºå åã®ååšããäžéœåãªããã«ã€ã³ã¿ãŒããš
ãã³ã®ç£çã«åœ±é¿ãäžããªãããã§ããããã®ç
ç±ã§ãéåžžã¯ãèªçºå åãé€å»ããªãã次ãã§ã
现èã液çžããåé¢ããããã®äžæž ã¯ãαâã€ã³
ã¿ãŒããšãã³ã«ãã€ãŠæ±æãããŠããç²è£œã®Î³â
ã€ã³ã¿ãŒããšãã³ãå«æããŠããããã®çç±ã¯ã
ã€ã³ã¿ãŒããšãã³ç£çã®ç¬¬ïŒæ®µéã«ãããŠïŒããª
ãã¡ãγâã€ã³ã¿ãŒããšãã³ç£çã®æ®µéã«ãã
ãŠïŒãαâã€ã³ã¿ãŒããšãã³ç£ç现èãå€å°ã®é
ã®ã€ã³ã¿ãŒããšãã³ãç£çããããã§ããã
床ã§ãïŒã48æéã奜ãŸããã¯12ã16æéå®æœã
ãããã®èªçºå åã¯ãææãªãã°æå®ã®æéïŒäŸ
ãã°ãïŒæéïŒã®åŸã«æŽæµã«ãã€ãŠé€å»ããŠãã
ããããã®å·¥çšã¯çç¥ããŠãããããã®çç±ã¯ã
èªçºå åã®ååšããäžéœåãªããã«ã€ã³ã¿ãŒããš
ãã³ã®ç£çã«åœ±é¿ãäžããªãããã§ããããã®ç
ç±ã§ãéåžžã¯ãèªçºå åãé€å»ããªãã次ãã§ã
现èã液çžããåé¢ããããã®äžæž ã¯ãαâã€ã³
ã¿ãŒããšãã³ã«ãã€ãŠæ±æãããŠããç²è£œã®Î³â
ã€ã³ã¿ãŒããšãã³ãå«æããŠããããã®çç±ã¯ã
ã€ã³ã¿ãŒããšãã³ç£çã®ç¬¬ïŒæ®µéã«ãããŠïŒããª
ãã¡ãγâã€ã³ã¿ãŒããšãã³ç£çã®æ®µéã«ãã
ãŠïŒãαâã€ã³ã¿ãŒããšãã³ç£ç现èãå€å°ã®é
ã®ã€ã³ã¿ãŒããšãã³ãç£çããããã§ããã
ãããã®ã€ã³ã¿ãŒããšãã³ã¯ãäºãã«å€ã®æãŠ
ã€ã«ã¹æŽ»æ§ãå¢åŒ·ããã®ã§ãαâããã³Î³âã€ã³
ã¿ãŒããšãã³ã®æ··åç©äžã®Î³âã€ã³ã¿ãŒããšãã³
ã®å®éã®éã¯ãæ€éç·ïŒç¬¬ïŒå³ïŒã«ãã€ãŠã®ã¿èš
ç®ããããšãã§ãããγâã€ã³ã¿ãŒããšãã³ã®é
ãèšç®ããããã«ãå¢åŒ·ãããå䟡ããã³æ··åç©
äžã®Î±âã€ã³ã¿ãŒããšãã³éãç¥ãããšãå¿ èŠã§
ãããåŸè ã®å€ã¯ãæ··åç©ãPHïŒã§åŠçãããã®
åŸããã滎å®ããããšã«ãã€ãŠæ±ºå®ããããšãã§
ããããã®çç±ã¯ãγâã€ã³ã¿ãŒããšãã³ããã
ã®PHå€ã§éžæçã«å解ããåŸãããã§ããã
ã€ã«ã¹æŽ»æ§ãå¢åŒ·ããã®ã§ãαâããã³Î³âã€ã³
ã¿ãŒããšãã³ã®æ··åç©äžã®Î³âã€ã³ã¿ãŒããšãã³
ã®å®éã®éã¯ãæ€éç·ïŒç¬¬ïŒå³ïŒã«ãã€ãŠã®ã¿èš
ç®ããããšãã§ãããγâã€ã³ã¿ãŒããšãã³ã®é
ãèšç®ããããã«ãå¢åŒ·ãããå䟡ããã³æ··åç©
äžã®Î±âã€ã³ã¿ãŒããšãã³éãç¥ãããšãå¿ èŠã§
ãããåŸè ã®å€ã¯ãæ··åç©ãPHïŒã§åŠçãããã®
åŸããã滎å®ããããšã«ãã€ãŠæ±ºå®ããããšãã§
ããããã®çç±ã¯ãγâã€ã³ã¿ãŒããšãã³ããã
ã®PHå€ã§éžæçã«å解ããåŸãããã§ããã
çŽç²ãªÎ³âã€ã³ã¿ãŒããšãã³ã¯ãç²è£œã®Î³âã€
ã³ã¿ãŒããšãã³äžã®Î±âã€ã³ã¿ãŒããšãã³éãé€
å»ããããšã«ãã€ãŠåŸãããããã®ç²è£œã®Î³âã€
ã³ã¿ãŒããšãã³ãã奜ãŸããã¯Î±âã€ã³ã¿ãŒããš
ãã³ãé€å»ããåã«ãïŒäŸãã°ãCPGâ350å€å
質ã¬ã©ã¹ç²åãElectronâNucleonic N.J.ç±³åœã
ã«ãã€ãŠïŒéšåçã«ç²Ÿè£œãããããŠæ¿çž®ãããäž
èšã®æ¹æ³ãçšããããšãã§ãããïŒã€ã®æ¹æ³ã¯ã
ïŒã€ã®åã®ã€ã³ã¿ãŒããšãã³ã®çžç°ãªãååé
ïŒÎ±ïŒ18000ã21000ãã«ãã³ãγïŒ40000ã45000
ãã«ãã³ïŒã«åºã¥ããã®ã§ãããã²ã«éïŒäŸã
ã°ãã»ãã¢ã¯ãªã«ïŒSephacrylïŒïŒ³â200ã¯ãã
ãã°ã©ãã€ãŒïŒã«ãã€ãŠå®æœãããã®ã§ãããä»
ã®æ¹æ³ã«ããã°ãγâã€ã³ã¿ãŒããšãã³ãæ±æã
ãŠããαâã€ã³ã¿ãŒããšãã³ããã»ãã¢ããŒã¹ã²
ã«ã«çµåããæâαâã€ã³ã¿ãŒããšãã³æäœã«ã
ã€ãŠçµåãããã
ã³ã¿ãŒããšãã³äžã®Î±âã€ã³ã¿ãŒããšãã³éãé€
å»ããããšã«ãã€ãŠåŸãããããã®ç²è£œã®Î³âã€
ã³ã¿ãŒããšãã³ãã奜ãŸããã¯Î±âã€ã³ã¿ãŒããš
ãã³ãé€å»ããåã«ãïŒäŸãã°ãCPGâ350å€å
質ã¬ã©ã¹ç²åãElectronâNucleonic N.J.ç±³åœã
ã«ãã€ãŠïŒéšåçã«ç²Ÿè£œãããããŠæ¿çž®ãããäž
èšã®æ¹æ³ãçšããããšãã§ãããïŒã€ã®æ¹æ³ã¯ã
ïŒã€ã®åã®ã€ã³ã¿ãŒããšãã³ã®çžç°ãªãååé
ïŒÎ±ïŒ18000ã21000ãã«ãã³ãγïŒ40000ã45000
ãã«ãã³ïŒã«åºã¥ããã®ã§ãããã²ã«éïŒäŸã
ã°ãã»ãã¢ã¯ãªã«ïŒSephacrylïŒïŒ³â200ã¯ãã
ãã°ã©ãã€ãŒïŒã«ãã€ãŠå®æœãããã®ã§ãããä»
ã®æ¹æ³ã«ããã°ãγâã€ã³ã¿ãŒããšãã³ãæ±æã
ãŠããαâã€ã³ã¿ãŒããšãã³ããã»ãã¢ããŒã¹ã²
ã«ã«çµåããæâαâã€ã³ã¿ãŒããšãã³æäœã«ã
ã€ãŠçµåãããã
æ¬çºæã®æ¹æ³ã®å¥œéœåã¯ãαâããã³Î³âã€ã³
ã¿ãŒããšãã³ãåäžã®çœè¡çå¹é€äžã§ïŒå·¥çšã§èª¿
補ããåŸããšããããšã§ãããã€ã³ã¿ãŒããšãã³
ïŒåäœã®èª¿è£œã³ã¹ãã¯ãææã«æžå°ããããªããª
ãã°ãã€ã³ã¿ãŒããšãã³ã®è£œé ã³ã¹ãã®å€§éšå
ããè¡æ¶²è©Šæã®éåããæ·¡é»èãç»åã®èª¿è£œãã
ã³çœè¡çã®ç²Ÿè£œãããªã€ãŠããããã§ãããæ¬çº
æã®æ¹æ³ã¯ãéå®çã§ãããå ¥æå¯èœãªçœè¡çã®
ã€ã³ã¿ãŒããšãã³ç£çã®ææãªå¢å ãå¯èœãšãã
ãã®ã§ããã
ã¿ãŒããšãã³ãåäžã®çœè¡çå¹é€äžã§ïŒå·¥çšã§èª¿
補ããåŸããšããããšã§ãããã€ã³ã¿ãŒããšãã³
ïŒåäœã®èª¿è£œã³ã¹ãã¯ãææã«æžå°ããããªããª
ãã°ãã€ã³ã¿ãŒããšãã³ã®è£œé ã³ã¹ãã®å€§éšå
ããè¡æ¶²è©Šæã®éåããæ·¡é»èãç»åã®èª¿è£œãã
ã³çœè¡çã®ç²Ÿè£œãããªã€ãŠããããã§ãããæ¬çº
æã®æ¹æ³ã¯ãéå®çã§ãããå ¥æå¯èœãªçœè¡çã®
ã€ã³ã¿ãŒããšãã³ç£çã®ææãªå¢å ãå¯èœãšãã
ãã®ã§ããã
æ¬çºæã®äžå±€ã®è©³çŽ°ãã以äžã®å®æœäŸã«ç€ºã
ããããã¯ãåèšå®æœäŸã®ä¿è·ã®ç¯å²ãéå®ãã
ãã®ã§ã¯ãªãã
ããããã¯ãåèšå®æœäŸã®ä¿è·ã®ç¯å²ãéå®ãã
ãã®ã§ã¯ãªãã
å®æœäŸ ïŒ
è¡æ¶²è©ŠæããACD溶液ïŒã¯ãšã³é
žããã³ã°ã«
ã³ãŒã¹ãå«æãã氎溶液ïŒäžã«ïŒïŒâã§ïŒæé貯
èµããããã®ããã«ããŠåŸãããïŒå®¹ééšã®çœè¡
çã³ã³ã»ã³ãã¬ãŒãããæ°·å·ãã0.83ïŒ å¡©åã¢ã³
ã¢ããŠã 氎溶液ïŒéééšãšæ··åããããã®æžæ¿æ¶²
ããèµ€è¡çã®æº¶è§£ãèµ·ãããŸã§ïŒïŒã10åéïŒæ°·
å·äžã«æŸçœ®ãããã®åŸãäžèšã®çµæïŒ æ å éãmgïŒ å¡©åã«ã«ã·ãŠã 175ã350 å¡©åã«ãªãŠã 300ã500 ç¡«é žãã°ãã·ãŠã ãŸãã¯å¡©åãã°ãã·ãŠã 175ã500 å¡©åãããªãŠã 5000ã7000 çé žæ°ŽçŽ ãããªãŠã 200ã3500 çé žäºæ°ŽçŽ ãããªãŠã 30ã150 ã°ã«ã³ãŒã¹ 500ã5500 ç¡é žç¬¬äºé ïŒã0.2mgïŒ ãæããæ é€å¹å°äžã«çœè¡çãæžæ¿ããã
ã³ãŒã¹ãå«æãã氎溶液ïŒäžã«ïŒïŒâã§ïŒæé貯
èµããããã®ããã«ããŠåŸãããïŒå®¹ééšã®çœè¡
çã³ã³ã»ã³ãã¬ãŒãããæ°·å·ãã0.83ïŒ å¡©åã¢ã³
ã¢ããŠã 氎溶液ïŒéééšãšæ··åããããã®æžæ¿æ¶²
ããèµ€è¡çã®æº¶è§£ãèµ·ãããŸã§ïŒïŒã10åéïŒæ°·
å·äžã«æŸçœ®ãããã®åŸãäžèšã®çµæïŒ æ å éãmgïŒ å¡©åã«ã«ã·ãŠã 175ã350 å¡©åã«ãªãŠã 300ã500 ç¡«é žãã°ãã·ãŠã ãŸãã¯å¡©åãã°ãã·ãŠã 175ã500 å¡©åãããªãŠã 5000ã7000 çé žæ°ŽçŽ ãããªãŠã 200ã3500 çé žäºæ°ŽçŽ ãããªãŠã 30ã150 ã°ã«ã³ãŒã¹ 500ã5500 ç¡é žç¬¬äºé ïŒã0.2mgïŒ ãæããæ é€å¹å°äžã«çœè¡çãæžæ¿ããã
ïŒéšã®çœè¡çæžæ¿æ¶²ã«å¯ŸããŠã0.83ïŒ
å¡©åã¢ã³
ã¢ããŠã 氎溶液10容ééšãçšãããšããçžéç¹ã
ãã€ãŠãåèšã®èµ€è¡çã®æº¶è§£æäœãç¹°ãè¿ããã
ãã®çœè¡çããåèšçµæã®æ é€å¹å°äžã«æžæ¿ãã
现èæ°ãïŒÃ107现èïŒmlã®å€ã«èª¿æŽããã
ã¢ããŠã 氎溶液10容ééšãçšãããšããçžéç¹ã
ãã€ãŠãåèšã®èµ€è¡çã®æº¶è§£æäœãç¹°ãè¿ããã
ãã®çœè¡çããåèšçµæã®æ é€å¹å°äžã«æžæ¿ãã
现èæ°ãïŒÃ107现èïŒmlã®å€ã«èª¿æŽããã
åèšæ é€å¹å°ã¯ãïŒmgïŒmlã®ããã°ãããªã³äž
å«è¡æž ïŒçŽïŒïŒ ïŒãå«æããŠãããåèšçŽ°èãã
37âã«ãããŠäžå®ã®æ¹æäžã«ã200IUïŒmlã®èªçº
å åäžå«ã®æ¿çž®ããαâã€ã³ã¿ãŒããšãã³ã§åŠç
ãããïŒæéåŸã现èã400èµ€è¡çåéåäœã®ã»
ã³ãã€ãŠã€ã«ã¹ã§èªçºãããã€ã³ããŠããŒã·ãšã³
ã¯ãèªçºã®åŸã18æé以å ã§çµãããäžæž ã®æãŠ
ã€ã«ã¹æ§Î±âã€ã³ã¿ãŒããšãã³ã®å䟡ã¯
54200IUïŒmlã§ãã€ããαâã€ã³ã¿ãŒããšãã³ã®
ç£çã®ããã«çšãã现èããåèšã®æ é€å¹å°ã§ïŒ
åæŽæµããåèšçœè¡çãæ é€å¹å°äžã«2.5Ã107现
èïŒmlã®æ¿åºŠã§æžæ¿ããããã®æ é€å¹å°ã¯ãïŒ
mgïŒmlã®ã°ãããªã³äžå«ã®ããè¡æž ïŒçŽïŒïŒ ïŒã
å«ãã§ããã次ãã§ã现èã15ugïŒmlã®ã³ã³ã«
ãããªã³ïŒ¡ã§åºæ¿ããããã®èªçºå åã¯ç³»ããé€
å»ããªãã€ããã€ã³ããŠããŒã·ãšã³ã37âã§äžå®
ã®æ¹æäžã«å®æœããèªçºåŸ16æé以å ã«äžæž ãé
å¿åé¢ã«ãã€ãŠçŽ°èããåãåºãããγâã€ã³ã¿
ãŒããšãã³ãå«ãäžæž ã®æãŠã€ã«ã¹æ§å䟡ã
WISHããçŸæ°ŽçŽ°èã«ãã€ãŠæ±ºå®ãããã®å䟡ã
ããαâã€ã³ã¿ãŒããšãã³æšæºãšæ¯èŒããŠïŒµïŒml
ïŒåäœïŒmlïŒã§è¡šãããïŒçŸåšã®ãšãããåœéç
ãªããγâã€ã³ã¿ãŒããšãã³æšæºçµæç©ã¯ãªãïŒã
äžæž ã®å䟡ã¯ã10600UïŒmlã§ãã€ãããããã¯
調補ããγâã€ã³ã¿ãŒããšãã³çµæç©ãαâã€ã³
ã¿ãŒããšãã³ããå«ãã§ããããå¢åŒ·ãããã¬ã
ã«ã®ãã®ã§ãã€ããããšã®ç©è³ªã®å䟡ããã³PHïŒ
ã§åŠçããå Žåã®å䟡ã«åºã¥ãã第ïŒå³ã®æ€éç·
ã«ããã°ãå®éã®Î³âã€ã³ã¿ãŒããšãã³ã®éã¯
1840UïŒmlã§ãã€ãã
å«è¡æž ïŒçŽïŒïŒ ïŒãå«æããŠãããåèšçŽ°èãã
37âã«ãããŠäžå®ã®æ¹æäžã«ã200IUïŒmlã®èªçº
å åäžå«ã®æ¿çž®ããαâã€ã³ã¿ãŒããšãã³ã§åŠç
ãããïŒæéåŸã现èã400èµ€è¡çåéåäœã®ã»
ã³ãã€ãŠã€ã«ã¹ã§èªçºãããã€ã³ããŠããŒã·ãšã³
ã¯ãèªçºã®åŸã18æé以å ã§çµãããäžæž ã®æãŠ
ã€ã«ã¹æ§Î±âã€ã³ã¿ãŒããšãã³ã®å䟡ã¯
54200IUïŒmlã§ãã€ããαâã€ã³ã¿ãŒããšãã³ã®
ç£çã®ããã«çšãã现èããåèšã®æ é€å¹å°ã§ïŒ
åæŽæµããåèšçœè¡çãæ é€å¹å°äžã«2.5Ã107现
èïŒmlã®æ¿åºŠã§æžæ¿ããããã®æ é€å¹å°ã¯ãïŒ
mgïŒmlã®ã°ãããªã³äžå«ã®ããè¡æž ïŒçŽïŒïŒ ïŒã
å«ãã§ããã次ãã§ã现èã15ugïŒmlã®ã³ã³ã«
ãããªã³ïŒ¡ã§åºæ¿ããããã®èªçºå åã¯ç³»ããé€
å»ããªãã€ããã€ã³ããŠããŒã·ãšã³ã37âã§äžå®
ã®æ¹æäžã«å®æœããèªçºåŸ16æé以å ã«äžæž ãé
å¿åé¢ã«ãã€ãŠçŽ°èããåãåºãããγâã€ã³ã¿
ãŒããšãã³ãå«ãäžæž ã®æãŠã€ã«ã¹æ§å䟡ã
WISHããçŸæ°ŽçŽ°èã«ãã€ãŠæ±ºå®ãããã®å䟡ã
ããαâã€ã³ã¿ãŒããšãã³æšæºãšæ¯èŒããŠïŒµïŒml
ïŒåäœïŒmlïŒã§è¡šãããïŒçŸåšã®ãšãããåœéç
ãªããγâã€ã³ã¿ãŒããšãã³æšæºçµæç©ã¯ãªãïŒã
äžæž ã®å䟡ã¯ã10600UïŒmlã§ãã€ãããããã¯
調補ããγâã€ã³ã¿ãŒããšãã³çµæç©ãαâã€ã³
ã¿ãŒããšãã³ããå«ãã§ããããå¢åŒ·ãããã¬ã
ã«ã®ãã®ã§ãã€ããããšã®ç©è³ªã®å䟡ããã³PHïŒ
ã§åŠçããå Žåã®å䟡ã«åºã¥ãã第ïŒå³ã®æ€éç·
ã«ããã°ãå®éã®Î³âã€ã³ã¿ãŒããšãã³ã®éã¯
1840UïŒmlã§ãã€ãã
æ¯èŒã®ããã«ãγâã€ã³ã¿ãŒããšãã³ç£çã®å
ã«ã»ã³ãã€ãŠã€ã«ã¹ãçšããªãã§çŽ°èãïŒæ¥éã€
ã³ããŠããŒããã以å€ã¯åèšããæ¹æ³ãç¹°ãè¿ã
ããã³ã³ã«ãããªã³ïŒ¡ã«ãã€ãŠç£çãããγâã€
ã³ã¿ãŒããšãã³å䟡ã¯ã340UïŒmlã§ãã€ãã
ã«ã»ã³ãã€ãŠã€ã«ã¹ãçšããªãã§çŽ°èãïŒæ¥éã€
ã³ããŠããŒããã以å€ã¯åèšããæ¹æ³ãç¹°ãè¿ã
ããã³ã³ã«ãããªã³ïŒ¡ã«ãã€ãŠç£çãããγâã€
ã³ã¿ãŒããšãã³å䟡ã¯ã340UïŒmlã§ãã€ãã
æ¯èŒã®ããã«ã第ïŒã®æ®µéãããªãã¡ãαâã€
ã³ã¿ãŒããšãã³ç£ç段éãçç¥ããŠãåé¢ããçœ
è¡çãçŽæ¥ã³ã³ã«ãããªã³ïŒ¡ã§èªçºãããç£çã
ããγâã€ã³ã¿ãŒããšãã³ã®å䟡ã¯450UïŒmlã§
ãã€ãã
ã³ã¿ãŒããšãã³ç£ç段éãçç¥ããŠãåé¢ããçœ
è¡çãçŽæ¥ã³ã³ã«ãããªã³ïŒ¡ã§èªçºãããç£çã
ããγâã€ã³ã¿ãŒããšãã³ã®å䟡ã¯450UïŒmlã§
ãã€ãã
αâã€ã³ã¿ãŒããšãã³ç£ç段éãçç¥ãããã€
èªçºã®åã«ïŒæéãçœè¡çã1500UïŒmlã®ããα
âãŸãã¯Î²âã€ã³ã¿ãŒããšãã³ã§åŠçïŒååæå
åºæ¿ïŒããå Žåã«ãç£çãããγâã€ã³ã¿ãŒããš
ãã³ã®å䟡ã¯2300UïŒmlã§ãã€ãã
èªçºã®åã«ïŒæéãçœè¡çã1500UïŒmlã®ããα
âãŸãã¯Î²âã€ã³ã¿ãŒããšãã³ã§åŠçïŒååæå
åºæ¿ïŒããå Žåã«ãç£çãããγâã€ã³ã¿ãŒããš
ãã³ã®å䟡ã¯2300UïŒmlã§ãã€ãã
å®æœäŸ ïŒ
æ é€å¹å°ãšããŠã€ãŒã°ã«â溶液ãçšãã
ïŒVirology 14ã359ïŒ1961幎ïŒïŒä»¥å€ã¯ãå®æœäŸ
ïŒã«åŸã€ãŠå®æœãããαâã€ã³ã¿ãŒããšãã³ã®å
䟡ã¯ã56000IUïŒmlã§ãã€ããç£çã®ç¬¬ïŒã®æ®µé
ã«ãããåäžã®æ é€å¹å°äžã®Î³âã€ã³ã¿ãŒããšã
ã³å䟡ã¯ã1680UïŒmlã§ãã€ãã
ïŒVirology 14ã359ïŒ1961幎ïŒïŒä»¥å€ã¯ãå®æœäŸ
ïŒã«åŸã€ãŠå®æœãããαâã€ã³ã¿ãŒããšãã³ã®å
䟡ã¯ã56000IUïŒmlã§ãã€ããç£çã®ç¬¬ïŒã®æ®µé
ã«ãããåäžã®æ é€å¹å°äžã®Î³âã€ã³ã¿ãŒããšã
ã³å䟡ã¯ã1680UïŒmlã§ãã€ãã
αâã€ã³ã¿ãŒããšãã³ç£çãçç¥ããå Žåã«ã
ç£çãããγâã€ã³ã¿ãŒããšãã³ã®å䟡ã¯
280UïŒmlã§ãã€ãã
ç£çãããγâã€ã³ã¿ãŒããšãã³ã®å䟡ã¯
280UïŒmlã§ãã€ãã
第ïŒå³ã¯ãαâã€ã³ã¿ãŒããšãã³ããã³Î³âã€
ã³ã¿ãŒããšãã³ã®æ··åç©äžã®Î³âã€ã³ã¿ãŒããšã
ã³éãèšå®ããããã®æ€éç·ãè¡šãããã®ã§ã
ãã
ã³ã¿ãŒããšãã³ã®æ··åç©äžã®Î³âã€ã³ã¿ãŒããšã
ã³éãèšå®ããããã®æ€éç·ãè¡šãããã®ã§ã
ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ è¡æ¶²ã®æ·¡é»èç»åãåé¢ããèµ€è¡çãé€å»
ããé©åœãªæ é€å¹å°äžã«çœè¡çãæžæ¿ãããããŠ
αâã€ã³ã¿ãŒããšãã³èªçºå åãçšãããã³Î³â
ã€ã³ã¿ãŒããšãã³èªçºå åãçšããŠåŠçããããš
ã«ãã€ãŠÎ±âããã³Î³âã€ã³ã¿ãŒããšãã³ã調補
ããæ¹æ³ã§ãã€ãŠã è¡æ¶²ã®çœè¡çïŒæ·¡é»èïŒç»åãåé¢ããèµ€è¡ç
ãé€å»ãé©åœãªæ é€å¹å°äžã«åèšçœè¡çãæžæ¿ã
ãåŸã«åŸãããæžæ¿æ¶²ãαâãŸãã¯Î²âã€ã³ã¿ãŒ
ããšãã³ã§äºååŠçããããšãαâã€ã³ã¿ãŒããš
ãã³èªçºå åãšæ¥è§Šãããããšãαâã€ã³ã¿ãŒã
ãšãã³ãå«æãã液äœãåèšçŽ°èããåé¢ããæ
æãªãã°Î±âã€ã³ã¿ãŒããšãã³ãååããããšã
é©åœãªæ é€å¹å°äžã§åèšçŽ°èãæŽæµãæžæ¿ããã
ããšãåè£ä¿é²å åãçšããŠåŠçããããšãγâ
ã€ã³ã¿ãŒããšãã³ãå«æãã液äœãåèšçŽ°èãã
åé¢ãææãªãã°Î³âã€ã³ã¿ãŒããšãã³ãåå
ãããããŠææãªãã°Î³âã€ã³ã¿ãŒããšãã³ãã
αâã€ã³ã¿ãŒããšãã³ãé€å»ããããšãã«ãã€ãŠ
åäžã®çœè¡çå¹é€äžã§é 次αâã€ã³ã¿ãŒããšãã³
ããã³Î³âã€ã³ã¿ãŒããšãã³ã調補ããããšãå«
ãã§ãªããαâããã³Î³âã€ã³ã¿ãŒããšãã³ã®èª¿
補æ¹æ³ã ïŒ åèšäºååŠçãã10ã500IUïŒmlã®Î±âãŸã
ã¯Î²âã€ã³ã¿ãŒããšãã³ãçšããŠå®æœããããšã
å«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšäºååŠçããïŒãïŒæéå®æœããããšã
å«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãŸãã¯ç¬¬ïŒé èšèŒã®
æ¹æ³ã ïŒ åèšäºååŠçãã35ã39âã§å®æœããããšã
å«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãã第ïŒé ãŸã§ã®ã
ãããã«èšèŒã®æ¹æ³ã ïŒ åèšÎ±âã€ã³ã¿ãŒããšãã³èªçºå åãšããŠã
ç²è£œãŸãã¯ç²Ÿè£œã®ã»ã³ãã€ãŠã€ã«ã¹ãçšããããš
ãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšã»ã³ãã€ãŠã€ã«ã¹ããïŒmlåœã100ã800
ã®èµ€è¡çåéåäœã§çšããããšãå«ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšÎ±âã€ã³ã¿ãŒããšãã³èªçºããïŒã48æ
éå®æœããããšãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãŸ
ãã¯ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšÎ±âã€ã³ã¿ãŒããšãã³èªçºãã35ã39â
ã§å®æœããããšãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã
ã第ïŒé ãŸã§ã®ããããã«èšèŒã®æ¹æ³ã ïŒ åèšåè£ä¿é²å åãšããŠãã³ã³ã«ãããªã³
ããã€ããã ã¢ã°ã«ããã³ãŸãã¯ã¹ã¿ãã€ãã³
ãã«ã¹ã®ãšã³ããããã·ã³ãçšããããšãå«ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒïŒ åèšÎ³âã€ã³ã¿ãŒããšãã³èªçºããïŒã48
æéå®æœããããšãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®æ¹æ³ã ïŒïŒ åèšã®åŸãããç²è£œÎ³âã€ã³ã¿ãŒããšãã³
ãéšåçã«ç²è£œãæ¿çž®ããããšãããã³ã²ã«é
ã«ãã€ãŠÎ±âã€ã³ã¿ãŒããšãã³ãé€å»ããããšãŸ
ãã¯åèšÎ±âã€ã³ã¿ãŒããšãã³ãæâαâã€ã³ã¿
ãŒããšãã³æäœãšçµåãããããšãå«ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé ãã第ïŒïŒé ãŸã§ã®ããããã«èš
èŒã®æ¹æ³ã ïŒïŒ åèšèµ€è¡çããå¡©åã¢ã³ã¢ããŠã ãçšãã
溶è¡ã«ãã€ãŠåèšæ·¡é»èç»åããé€å»ããããšã
å«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãã第ïŒïŒé ãŸã§ã®
ããããã«èšèŒã®æ¹æ³ã ïŒïŒ åèšæ é€å¹å°ãšããŠã175ã350mgïŒã®å¡©
åã«ã«ã·ãŠã ã300ã500mgïŒã®å¡©åã«ãªãŠã ã
175ã500mgïŒã®ç¡«é žãã°ãã·ãŠã ãŸãã¯åœéã®
å¡©åãã°ãã·ãŠã ã5000ã7000mgïŒã®å¡©åãã
ãªãŠã ã200ã3500mgïŒã®çé žæ°ŽçŽ ãããªãŠã ã
30ã150mgïŒã®çé žäºæ°ŽçŽ ãããªãŠã ã500ã
5500mgïŒã®ã°ã«ã³ãŒã¹ããã³ä»»æã«0.0ã0.2
mgïŒã®ç¡é žç¬¬äºéããã³0.5ã10ïŒ ã®è¡æž ãŸã
ã¯è¡æž ã¿ã³ãã¯ïŒ0.5ãïŒmgïŒmlïŒãå«æããæ°Ž
溶液ãçšããããšãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
ãã第ïŒïŒé ãŸã§ã®ããããã«èšèŒã®æ¹æ³ã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU2251/4237/83 | 1983-12-13 | ||
HU834237A HU192254B (en) | 1983-12-13 | 1983-12-13 | Process for producing human leucocite and human gamma interferons in consecutive steps |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60139700A JPS60139700A (ja) | 1985-07-24 |
JPH0475920B2 true JPH0475920B2 (ja) | 1992-12-02 |
Family
ID=10967404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59260115A Granted JPS60139700A (ja) | 1983-12-13 | 1984-12-11 | αâããã³Î³âã€ã³ã¿ãŒããšãã³ã®èª¿è£œæ¹æ³ |
Country Status (10)
Country | Link |
---|---|
US (1) | US4696899A (ja) |
EP (1) | EP0146107A3 (ja) |
JP (1) | JPS60139700A (ja) |
BG (1) | BG50035A3 (ja) |
CS (1) | CS260049B2 (ja) |
DD (1) | DD266002A7 (ja) |
FI (1) | FI844897L (ja) |
HU (1) | HU192254B (ja) |
RO (1) | RO93446B (ja) |
SU (1) | SU1713591A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU201100B (en) * | 1988-03-04 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Process for large-scale production of high purity human leukocyte alpha interferon with reduced endotoxin content and with improved therapeutic effect |
DE69324671D1 (de) * | 1992-02-10 | 1999-06-02 | Interferon Sciences Inc | Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
CA2078805C (en) * | 1992-09-22 | 1997-02-25 | Intelcor Biotech Enterprises Inc. | Cytokine preparation |
HU222980B1 (hu) * | 1998-03-13 | 2004-01-28 | Acapi, Alpha-Chem Advanced Pharmaceutical Industries S.A.E. | Eljárás humán Alfa-interferon elÅállÃtására |
WO1999050390A1 (en) | 1998-03-30 | 1999-10-07 | Bionative Ab | Methionin containing animal cell culture medium and its use |
SE519827C2 (sv) | 1998-03-30 | 2003-04-15 | Viranative Ab | NÀringsmedium innehållande metionin samt anvÀndning av detta |
US6433144B1 (en) | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
US7341121B2 (en) * | 2004-01-09 | 2008-03-11 | Electric Mobility Corp | Vehicle with improved turning |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55154919A (en) * | 1979-05-24 | 1980-12-02 | Hayashibara Takeshi | Preparation of interferon |
SE8204382L (sv) * | 1981-07-21 | 1983-01-22 | Hayashibara Biochem Lab | Sett att framstella malcellysfaktor och anvendning derav |
DE3136166A1 (de) * | 1981-09-12 | 1983-04-14 | Blutspendedienst der LandesverbÀnde des Deutschen Roten Kreuzes Niedersachsen, Oldenburg und Bremen GemeinnÌtzige GmbH, 3257 Springe | Verfahren zur gewinnung von interferon-(alpha) und interferon-(gamma) |
HU184972B (en) * | 1981-12-01 | 1984-11-28 | Egyt Gyogyszervegyeszeti Gyar | Process for preparing human gamma interferone |
-
1983
- 1983-12-13 HU HU834237A patent/HU192254B/hu unknown
-
1984
- 1984-12-10 US US06/681,451 patent/US4696899A/en not_active Expired - Fee Related
- 1984-12-11 JP JP59260115A patent/JPS60139700A/ja active Granted
- 1984-12-11 EP EP84115123A patent/EP0146107A3/de not_active Withdrawn
- 1984-12-11 BG BG067852A patent/BG50035A3/xx unknown
- 1984-12-11 SU SU847773679A patent/SU1713591A1/ru active
- 1984-12-11 FI FI844897A patent/FI844897L/fi not_active Application Discontinuation
- 1984-12-11 DD DD84270606A patent/DD266002A7/de not_active IP Right Cessation
- 1984-12-11 RO RO116628A patent/RO93446B/ro unknown
- 1984-12-12 CS CS849696A patent/CS260049B2/cs unknown
Also Published As
Publication number | Publication date |
---|---|
FI844897A0 (fi) | 1984-12-11 |
CS260049B2 (en) | 1988-11-15 |
SU1713591A1 (ru) | 1992-02-23 |
EP0146107A2 (de) | 1985-06-26 |
RO93446A (ro) | 1988-03-30 |
HUT38399A (en) | 1986-05-28 |
HU192254B (en) | 1987-05-28 |
EP0146107A3 (de) | 1987-12-16 |
BG50035A3 (en) | 1992-04-15 |
FI844897L (fi) | 1985-06-14 |
RO93446B (ro) | 1988-04-02 |
CS969684A2 (en) | 1988-01-15 |
DD266002A7 (de) | 1989-03-22 |
US4696899A (en) | 1987-09-29 |
JPS60139700A (ja) | 1985-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5177194A (en) | Process for purifying immune serum globulins | |
US4210580A (en) | Process for separation and isolation of AHF and fibronectin from blood plasma | |
US7125552B2 (en) | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates | |
RU94045873A (ru) | ÐПЌпПзОÑÐžÑ Ð°Ð»ÑÑа-ОМÑеÑÑеÑПМа О ÑпПÑПб ее пПлÑÑÐµÐœÐžÑ ÐžÐ· лейкПÑОÑПв кÑПвО ÑелПвека | |
JPS6149959B2 (ja) | ||
US4087415A (en) | Antithrombin III | |
US4764279A (en) | Process for preparing the principal proteins of hemolyzed blood in the non-denatured form | |
JPH0475920B2 (ja) | ||
US4670544A (en) | Process for the manufacture of the cold insoluble globulin and pharmaceutical preparation containing it | |
US4296025A (en) | Process for preparing human interferon | |
CA1211711A (en) | Removal of impurities from human leukocyte interferon preparations | |
JPS59222420A (ja) | 第ïŒå åå«æ補å€ã®è£œé æ³ | |
US3975344A (en) | Interferon purification | |
US4686284A (en) | Production of monomeric human γ-interferon | |
US4977246A (en) | High recovery process for antihemophilic factor | |
US4018885A (en) | Steroid-binding globulin and process for preparing it and antibodies thereto | |
JPS58502032A (ja) | ããïœâã€ã³ã¿âãã§ãã³ã®è£œé æ¹æ³ | |
US5391713A (en) | Interferon purification process | |
FI98218C (fi) | Interferonin puhdistusmenetelmÀ | |
AT391482B (de) | Verfahren zur industriellen herstellung von hochreinem menschlichem leukozyteninterferon | |
CA2234396C (en) | Method for production of native human leukocyte (alpha) interferon | |
FI80599C (fi) | Foerfarande foer rening av maenniskoleukocytinterferon. | |
KR850000145B1 (ko) | Bí ê°ìŒ ë°ìŽë¬ì€ íë©Ž íìì ë¶ëŠ¬ ì ì ë°©ë² | |
US3477911A (en) | Method of production of urokinase | |
JPS6236487B2 (ja) |